$24.58
+3.9%Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Last Annual Value
0.00
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
| Company | Total Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Elanco Animal Health Incorporated NYSE:ELAN | 0.00 | N/A | N/A | N/A | |
![]() Revvity, Inc. NYSE:RVTY | 1.16M | -88.1% | -59.8% | N/A | |
![]() Neurocrine Biosciences, Inc. NASDAQ:NBIX | 1.95B | 6.2% | 14.4% | 22.0% | |
![]() Align Technology, Inc. NASDAQ:ALGN | 15.92M | -28.4% | -39.6% | -26.7% | |
![]() The Ensign Group, Inc. NASDAQ:ENSG | 235.35M | 139.0% | 76.4% | 35.2% | |
![]() Encompass Health Corporation NYSE:EHC | 171.30M | 5.2% | N/A | 13.9% | |
![]() Solventum Corporation NYSE:SOLV | 0.00 | N/A | N/A | N/A | |
![]() Viatris Inc. NASDAQ:VTRS | 921.40M | -11.6% | 23.9% | 6.7% | |
![]() Qiagen N.V. NYSE:QGEN | 259.91M | -12.6% | 7.1% | 5.7% | |
![]() Revolution Medicines, Inc. NASDAQ:RVMD | 1.64B | 12.4% | 28.5% | N/A |
Continue your ELAN research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.